Bexitrol® F metered dose inhaler is a combination of Salmeterol Xinafoate BP and Fluticasone Propionate BP. Salmeterol Xinafoate is a selective, long acting beta-2 agonist used in the treatment of asthma and other forms of diffuse airways obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systematic effects at usual dose. Bexitrol® F is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting beta-2-agonist or patients already adequately controlled on both inhaled corticosteroids and long-acting beta-2-agonist
Bexitrol F HFA Inhaler
Adults and adolescents 12 years and older-
Two inhalations of 25 mg Salmeterol and 50 mg Fluticasone Propionate twice daily. or,
Two inhalations of 25 mg Salmeterol and 125 mg Fluticasone Propionate twice daily. or,
Two inhalations of 25 mg Salmeterol and 250 mg Fluticasone Propionate twice daily.